Infantile hypertrophic pyloric stenosis: maternal diabetes and perinatal exposure to non-macrolide antibiotics

J Perinatol. 2023 Apr;43(4):465-469. doi: 10.1038/s41372-023-01619-2. Epub 2023 Jan 26.

Abstract

Objective: Infant exposure to macrolide antibiotics is a risk factor for infantile hypertrophic pyloric stenosis (IHPS). The aim of the study was to establish whether perinatal exposure to non-macrolide antibiotics was a risk factor for IHPS.

Study design: A retrospective matched case-control study was performed using a database including all children born at Soroka University Medical Centre between 2006 and 2018. Cases and controls were compared using Student T-test and multiple logistic regression.

Result: Of 189 461 children in the database, 63 infants were diagnosed with IHPS and underwent pyloromyotomy. There was no association between non-macrolide antibiotic exposure and IHPS. Maternal diabetes (DM) had an adjusted odds ratio for infants developing IHPS of 4.53 (p = 0.004).

Conclusion: The lack of association between exposure to non-macrolide antibiotics and IHPS suggests a quality unique to macrolides. An association between DM and IHPS may suggest elevated levels of IGF-1 have a role.

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Case-Control Studies
  • Child
  • Diabetes, Gestational* / drug therapy
  • Diabetes, Gestational* / epidemiology
  • Female
  • Humans
  • Infant
  • Macrolides / adverse effects
  • Pregnancy
  • Pyloric Stenosis, Hypertrophic* / drug therapy
  • Pyloric Stenosis, Hypertrophic* / etiology
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Macrolides